Zeria's functional dyspepsia drug nears first filing
This article was originally published in Scrip
Zeria and development partner Astellas are preparing to make an approval submission in Japan for acotiamide (Z-338), a potential first-in-class drug for functional dyspepsia (FD).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.